PMID: 15230287Jul 3, 2004Paper

Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus

Lupus
Russell P RotherE W McCroskery

Abstract

The importance of the complement system in the pathophysiology of systemic lupus erythematosus (SLE) is clear although individual complement components play very different roles in the disease process. Early complement proteins are critical in the clearance of immune complexes and apoptotic bodies, and their absence predisposes individuals to SLE. Conversely, activation of terminal complement is associated with exacerbations of disease and damage to tissues and organs, particularly in lupus nephritis. Monoclonal antibodies that specifically inhibit terminal complement activation while preserving the critical functions of the early complement cascade have now been developed. These antibodies target the C5 complement protein, blocking its cleavage and the subsequent generation of potent proinflammatory molecules. Anti-C5 therapeutics have recently been investigated in an animal model of SLE and in a Phase I single dose study in humans. The results of these studies and the multiple roles of complement in SLE are discussed.

References

Sep 11, 1991·Kidney International·M SchulzeO Gotze
May 1, 1985·Progress in Cardiovascular Diseases·A AnsariH D Bates
Dec 1, 1981·The Journal of Experimental Medicine·G BieseckerD Koffler
Nov 9, 1995·The New England Journal of Medicine·P HillmenJ V Dacie
Aug 1, 1995·Nature Medicine·L A Matis, S A Rollins
May 1, 1993·Journal of the American Academy of Dermatology·K F Helm, M S Peters
Mar 1, 1995·Clinical Immunology and Immunopathology·J M PorcelD Vergani
Jan 1, 1994·Annual Review of Immunology·C Gerard, N P Gerard
Mar 1, 1994·British Journal of Rheumatology·M ShinguM Nobunaga
Jan 1, 1993·Immunologic Research·A Nicholson-Weller, J A Halperin
Jun 1, 1996·Arthritis and Rheumatism·J B Lefkowith, G S Gilkeson
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·Y WangL A Matis
Sep 1, 1996·Clinical and Experimental Immunology·J E TeixeiraJ E Barbosa
Sep 1, 1996·Current Opinion in Rheumatology·S G West
Oct 20, 1998·Immunobiology·M J WalportM Botto
Jan 12, 1999·Lupus·G G Illei, J H Klippel
Mar 11, 1999·Experimental and Clinical Immunogenetics·M Botto
May 14, 1999·Arthritis and Rheumatism·Z AmouraS Koutouzov
Aug 4, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·C C MokC S Lau
Aug 10, 2000·The Journal of Experimental Medicine·P R TaylorM J Walport
Feb 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·J S NavratilJ M Ahearn
Mar 22, 2001·Archives of Pathology & Laboratory Medicine·M D HughsonR McMurray
Apr 5, 2001·The New England Journal of Medicine·M J Walport
Jul 19, 2001·Revista Da Sociedade Brasileira De Medicina Tropical·A A MachadoE A Donadi
Sep 5, 2001·Molecular Immunology·Z FishelsonD Mevorach
Sep 11, 2001·The American Journal of Pathology·A DengG W Rebeck
Jan 5, 2002·Expert Opinion on Investigational Drugs·G G Illei, L Czirják
Jan 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Shirit EinavMichael C Carroll
Feb 22, 2002·Journal of the American Society of Nephrology : JASN·José VilarMartine Leliévre-Pégorier
Apr 16, 2002·Arthritis and Rheumatism·Kevin A DaviesMark J Walport
Jul 12, 2002·Arthritis Research·Mark J Walport

❮ Previous
Next ❯

Citations

May 4, 2013·Human Immunology·Renato M NisiharaIara J Messias-Reason
Aug 26, 2006·Nature Clinical Practice. Rheumatology·David Isenberg, Anisur Rahman
Jul 22, 2010·Nature Reviews. Rheumatology·Rona M SmithDavid R W Jayne
Dec 29, 2009·Médecine sciences : M/S·Alain BeckNathalie Corvaia
Dec 29, 2009·Médecine sciences : M/S·Gérard SociéRégis Peffault de Latour
Apr 4, 2006·Current Opinion in Rheumatology·Margrit WiesendangerBetty Diamond
May 7, 2013·BMC Medicine·Natasha JordanDavid P D'Cruz
Dec 17, 2009·Therapeutics and Clinical Risk Management·Richard KellyAnita Hill
May 1, 2007·Expert Opinion on Therapeutic Targets·Konstantin Petrukhin
Nov 1, 2007·Expert Review of Clinical Immunology·Chi Chiu Mok
Mar 5, 2014·Expert Opinion on Emerging Drugs·Chi Chiu Mok
Feb 13, 2010·Expert Opinion on Emerging Drugs·Chi Chiu Mok
Oct 27, 2006·Expert Opinion on Emerging Drugs·Chi Chiu Mok
Jul 23, 2013·Reumatología clinica·Jaime Calvo-AlénUNKNOWN Sociedad Española de Reumatología
Apr 10, 2012·Reumatología clinica·Walter A Sifuentes GiraldoAntonio C Zea Mendoza
Jul 7, 2010·European Journal of Internal Medicine·Saleh RachidiAli T Taher
Oct 31, 2007·Autoimmunity Reviews·A TincaniS Sozzani
Apr 21, 2007·Journal of Molecular Biology·Pietro RoversiSusan M Lea
Dec 4, 2014·Translational Research : the Journal of Laboratory and Clinical Medicine·Edwin K S Wong, David Kavanagh
Jul 21, 2007·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Yuyang FuChandra Mohan
Oct 25, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Davood RostamzadehMehdi Yousefi
Apr 6, 2005·Lupus·S Vasoo, G R V Hughes
Mar 1, 2005·Lupus·H Tahir, D A Isenberg
Apr 20, 2019·Frontiers in Immunology·Joshua M Thurman, Roshini Yapa
Jul 30, 2020·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Louise OniKjell Tullus
Aug 10, 2019·BioMed Research International·Dominik Samotij, Adam Reich
Apr 10, 2017·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Joshua M Thurman
Dec 29, 2020·Frontiers in Immunology·Marion OrtPriska Kaufmann
Feb 3, 2021·The Journal of Clinical Investigation·Sarthak Gupta, Mariana J Kaplan
Aug 7, 2007·Medicina clínica·Juan Carlos Bermell Serrano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.